Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments.

[1]  S. Mitragotri,et al.  Treating Tumors at Low Drug Doses Using an Aptamer-Peptide Synergistic Drug Conjugate. , 2018, Angewandte Chemie.

[2]  Kristy M Ainslie,et al.  A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. , 2018, JCI insight.

[3]  H. Hackl,et al.  Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. , 2018, JCI insight.

[4]  A. Conesa,et al.  Tumor microenvironment-targeted poly-L-glutamic acid-based combination conjugate for enhanced triple negative breast cancer treatment. , 2018, Biomaterials.

[5]  A. Singh,et al.  Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages , 2018, Scientific Reports.

[6]  Charles Lee,et al.  Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice , 2018, Experimental & Molecular Medicine.

[7]  J. Munson,et al.  Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression , 2018, BMC Cancer.

[8]  Li Tang,et al.  Enhancing T cell therapy through TCR signaling-responsive nanoparticle drug delivery , 2018, Nature Biotechnology.

[9]  A. Yoshimura,et al.  Inhibition of Nr4a Receptors Enhances Antitumor Immunity by Breaking Treg-Mediated Immune Tolerance. , 2018, Cancer research.

[10]  Androulla N. Miliotou,et al.  CAR T-cell Therapy: A New Era in Cancer Immunotherapy. , 2018, Current pharmaceutical biotechnology.

[11]  F. Giles,et al.  Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) , 2018, Journal of Immunotherapy for Cancer.

[12]  T. Seierstad,et al.  Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer , 2018, British Journal of Cancer.

[13]  D. Waxman,et al.  Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. , 2018, Cancer letters.

[14]  A. Ganti,et al.  Predictive biomarkers for immune checkpoint inhibitor therapy: we need to keep searching. , 2018, Journal of thoracic disease.

[15]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[16]  P. Chow,et al.  Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy , 2018, Gut.

[17]  D. McNeel.  Therapeutic Cancer Vaccines: How Much Closer Are We? , 2017, BioDrugs.

[18]  Kathryn Prame Kumar,et al.  Partners in crime: neutrophils and monocytes/macrophages in inflammation and disease , 2018, Cell and Tissue Research.

[19]  K. Leandersson,et al.  Docetaxel promotes the generation of anti‐tumorigenic human macrophages , 2018, Experimental cell research.

[20]  S. Pollack,et al.  Limited activity of metronomic cyclophosphamide and pembrolizumab for soft tissue sarcomas. , 2018, Translational gastroenterology and hepatology.

[21]  Leon Y. Cai,et al.  Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[22]  S. Mitragotri,et al.  Schedule dependent synergy of gemcitabine and doxorubicin: Improvement of in vitro efficacy and lack of in vitro‐in vivo correlation , 2018, Bioengineering & translational medicine.

[23]  K. Flaherty,et al.  Mechanisms of resistance to immune checkpoint inhibitors , 2018, British Journal of Cancer.

[24]  E. Schadt,et al.  Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. , 2017, European urology.

[25]  S. Mitragotri,et al.  A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[26]  P. Rai,et al.  Cancer nanomedicine: a review of recent success in drug delivery , 2017, Clinical and Translational Medicine.

[27]  Jingwei Shao,et al.  A carrier-free dual-drug nanodelivery system functionalized with aptamer specific targeting HER2-overexpressing cancer cells. , 2017, Journal of materials chemistry. B.

[28]  Juanita Lopez,et al.  Combining DNA damaging therapeutics with immunotherapy: more haste, less speed , 2017, British Journal of Cancer.

[29]  F. Gauffre,et al.  Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells. , 2017, International journal of pharmaceutics.

[30]  C. Van Waes,et al.  Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma , 2017, Cancer Immunology Research.

[31]  A. Nowak,et al.  A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice , 2017, BMC Cancer.

[32]  Lipeng Liu,et al.  Chemotherapy oxaliplatin sensitizes prostate cancer to immune checkpoint blockade therapies via stimulating tumor immunogenicity. , 2017, Molecular medicine reports.

[33]  S. Mitragotri,et al.  A review on engineering polymer drug conjugates to improve combination chemotherapy , 2017 .

[34]  S. Mitragotri,et al.  Microfluidic co‐culture devices to assess penetration of nanoparticles into cancer cell mass , 2017, Bioengineering & translational medicine.

[35]  L. Anelli,et al.  CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds? , 2017, Expert review of hematology.

[36]  L. S. Angelo,et al.  Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models , 2017, Front. Immunol..

[37]  K. Allison,et al.  Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial , 2017, JAMA oncology.

[38]  Dong-Wan Kim,et al.  Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma , 2017, Oncotarget.

[39]  M. Colombo,et al.  Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors , 2017, Clinical Cancer Research.

[40]  S. Basu,et al.  Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro. , 2017, Toxicology in vitro : an international journal published in association with BIBRA.

[41]  Qiang Zhang,et al.  Combination antitumor therapy with targeted dual‐nanomedicines☆ , 2017, Advanced drug delivery reviews.

[42]  Weiwei Wang,et al.  Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model. , 2017, Biochemical and biophysical research communications.

[43]  B. Guo,et al.  M2 tumor-associated macrophages produce interleukin-17 to suppress oxaliplatin-induced apoptosis in hepatocellular carcinoma , 2017, Oncotarget.

[44]  Peng Li,et al.  Current status and perspectives of patient-derived xenograft models in cancer research , 2017, Journal of Hematology & Oncology.

[45]  J. García-Pedrero,et al.  Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models1 , 2017, Neoplasia.

[46]  R. Gordon,et al.  Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer , 2017, Asia-Pacific journal of oncology nursing.

[47]  P. Greenberg,et al.  Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. , 2017, Cancer cell.

[48]  J. Hansson,et al.  Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer. , 2017, Clinical immunology.

[49]  K. Rege,et al.  Emerging applications of exosomes in cancer therapeutics and diagnostics , 2017, Bioengineering & translational medicine.

[50]  D. Amadori,et al.  Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas , 2017, OncoTargets and therapy.

[51]  Xianhe Xie,et al.  Efficacy and Toxicity of Low-Dose versus Conventional-Dose Chemotherapy for Malignant Tumors: a Meta-Analysis of 6 Randomized Controlled Trials , 2017, Asian Pacific journal of cancer prevention : APJCP.

[52]  S. Davaran,et al.  Liposome-based drug co-delivery systems in cancer cells. , 2017, Materials science & engineering. C, Materials for biological applications.

[53]  James R. Swartz,et al.  Virus‐like particles: Next‐generation nanoparticles for targeted therapeutic delivery , 2017, Bioengineering & translational medicine.

[54]  Xun Sun,et al.  Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy. , 2017, Molecular pharmaceutics.

[55]  P. Kantoff,et al.  Cancer nanomedicine: progress, challenges and opportunities , 2016, Nature Reviews Cancer.

[56]  Xun Sun,et al.  Development of a multi-target peptide for potentiating chemotherapy by modulating tumor microenvironment. , 2016, Biomaterials.

[57]  A. Jimeno,et al.  Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. , 2016, Cancer research.

[58]  S. Gettinger,et al.  Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  C. Balañà,et al.  Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  K. Leong,et al.  Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. , 2016, Biomaterials.

[61]  Yuhua Wang,et al.  Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach. , 2016, Cancer letters.

[62]  Ralph R. Weichselbaum,et al.  Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy , 2016, Nature Communications.

[63]  E. Elkord,et al.  Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting , 2016, Vaccines.

[64]  K. Sankhala,et al.  Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives , 2016, Advances in Therapy.

[65]  S. Mitragotri,et al.  DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[66]  Laura M Ensign,et al.  PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. , 2016, Advanced drug delivery reviews.

[67]  Yi Zhi,et al.  Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis , 2016, OncoTargets and therapy.

[68]  Zhen Gu,et al.  Recent advances of cocktail chemotherapy by combination drug delivery systems. , 2016, Advanced drug delivery reviews.

[69]  S. Mitragotri,et al.  Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.

[70]  J. Taube,et al.  The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder , 2016, Oncoimmunology.

[71]  Yi-Chiang Hsu,et al.  Low‐dose metronomic chemotherapy with cisplatin enhanced immunity in a murine model of ectopic cervical cancer , 2016, Clinical and experimental pharmacology & physiology.

[72]  R. Weissleder,et al.  Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. , 2016, Immunity.

[73]  S. Pezzotto,et al.  Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response , 2016, Cancer Chemotherapy and Pharmacology.

[74]  D. Yoon,et al.  Mucin 1-mediated chemo-resistance in lung cancer cells , 2016, Oncogenesis.

[75]  Jian Huang,et al.  Anthracyclines potentiate anti-tumor immunity: A new opportunity for chemoimmunotherapy. , 2015, Cancer letters.

[76]  L. Zitvogel,et al.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.

[77]  Ralph Weissleder,et al.  Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug , 2015, Nature Communications.

[78]  Edina M K da Silva,et al.  Combination chemotherapy versus single-agent chemotherapy during preoperative chemoradiation for resectable rectal cancer. , 2015, The Cochrane database of systematic reviews.

[79]  B. Johnston,et al.  Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies , 2015, Oncotarget.

[80]  S. H. van der Burg,et al.  A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[81]  J. Sparano,et al.  Progress in adjuvant chemotherapy for breast cancer: an overview , 2015, BMC Medicine.

[82]  S. Mitragotri,et al.  Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[83]  R. Talamini,et al.  Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy , 2015, Journal of Translational Medicine.

[84]  N. Vigneron.  Human Tumor Antigens and Cancer Immunotherapy , 2015, BioMed research international.

[85]  S. Ran.  The Role of TLR4 in Chemotherapy-Driven Metastasis. , 2015, Cancer research.

[86]  L. Emens,et al.  The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies , 2015, Cancer Immunology Research.

[87]  S. Malkoski,et al.  Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors , 2015, Oncogene.

[88]  Christopher J. Kane,et al.  Immunosuppressive plasma cells impede T cell-dependent immunogenic chemotherapy , 2015, Nature.

[89]  C. Vetro,et al.  Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy , 2015, British journal of haematology.

[90]  D. Waxman,et al.  Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+ T-cell responses and immune memory , 2015, Oncoimmunology.

[91]  Honggang Yu,et al.  Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells , 2015, Molecular medicine reports.

[92]  Zhi-jun Chen,et al.  Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer , 2015, The Journal of international medical research.

[93]  A. Nowak,et al.  Tumor‐infiltrating dendritic cells exhibit defective cross‐presentation of tumor antigens, but is reversed by chemotherapy , 2015, European journal of immunology.

[94]  L. Pusztai,et al.  PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer , 2014, Cancer Immunology Research.

[95]  William Y. Kim,et al.  Nanoparticles with Precise Ratiometric Co‐Loading and Co‐Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer , 2014, Advanced functional materials.

[96]  M. Sade-Feldman,et al.  Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. , 2014, Cancer research.

[97]  D. Waxman,et al.  Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model. , 2014, Cancer Letters.

[98]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[99]  S. Ran,et al.  Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. , 2014, Cancer research.

[100]  B. Weaver,et al.  How Taxol/paclitaxel kills cancer cells , 2014, Molecular biology of the cell.

[101]  F. Ghiringhelli,et al.  Prospective Study of the Evolution of Blood Lymphoid Immune Parameters during Dacarbazine Chemotherapy in Metastatic and Locally Advanced Melanoma Patients , 2014, PloS one.

[102]  J. Barreto,et al.  Antineoplastic Agents and the Associated Myelosuppressive Effects , 2014, Journal of pharmacy practice.

[103]  Susan A. Watson,et al.  Camptothecin prodrug block copolymer micelles with high drug loading and target specificity , 2014 .

[104]  Swaleha Zubair,et al.  Physicochemical Properties of Nanomaterials: Implication in Associated Toxic Manifestations , 2014, BioMed research international.

[105]  R. Zhang,et al.  Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates , 2014, Proceedings of the National Academy of Sciences.

[106]  D. Munn,et al.  Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. , 2014, Cancer research.

[107]  T. Hickish,et al.  Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. , 2014, The Lancet. Oncology.

[108]  Dinesh Vyas,et al.  Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis , 2014, OncoTargets and therapy.

[109]  A. Valachis,et al.  Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2: a literature-based meta-analysis of randomized studies. , 2014, Lung cancer.

[110]  Erik C. Dreaden,et al.  A Nanoparticle-Based Combination Chemotherapy Delivery System for Enhanced Tumor Killing by Dynamic Rewiring of Signaling Pathways , 2014, Science Signaling.

[111]  Lei Lu,et al.  Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs , 2014, Journal of Translational Medicine.

[112]  H. Pandha,et al.  The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer , 2014, Cancer Immunology, Immunotherapy.

[113]  David Escors,et al.  Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. , 2014, New journal of science.

[114]  K. Ulbrich,et al.  HPMA copolymer-bound doxorubicin induces immunogenic tumor cell death. , 2013, Current medicinal chemistry.

[115]  S. Mitragotri,et al.  Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles. , 2013, ACS nano.

[116]  Cara C. Schafer,et al.  Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. , 2013, Cancer research.

[117]  G. Beatty,et al.  Harnessing the antitumor potential of macrophages for cancer immunotherapy , 2013, Oncoimmunology.

[118]  A. Epstein,et al.  Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy , 2013, Journal of immunotherapy.

[119]  Patrick Couvreur,et al.  Stimuli-responsive nanocarriers for drug delivery. , 2013, Nature materials.

[120]  Darrell J Irvine,et al.  Engineering synthetic vaccines using cues from natural immunity. , 2013, Nature materials.

[121]  Nina Daschil,et al.  Lapatinib and doxorubicin enhance the Stat1‐dependent antitumor immune response , 2013, European journal of immunology.

[122]  S. Ferrone,et al.  Chemotherapy‐induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death , 2013, International journal of cancer.

[123]  Maria Jure-Kunkel,et al.  Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models , 2013, Cancer Immunology, Immunotherapy.

[124]  D. Yardley,et al.  Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes , 2013, International journal of breast cancer.

[125]  L. Bracci,et al.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer , 2013, Cell Death and Differentiation.

[126]  F. Végran,et al.  Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells , 2013, PloS one.

[127]  Justin J. Wilson,et al.  Monofunctional and higher-valent platinum anticancer agents. , 2013, Inorganic chemistry.

[128]  R. Kaneno,et al.  Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy , 2013, International journal of cancer.

[129]  K. Na,et al.  Doxorubicin loading fucoidan acetate nanoparticles for immune and chemotherapy in cancer treatment. , 2013, Carbohydrate polymers.

[130]  Manu M. Joseph,et al.  PST-Gold nanoparticle as an effective anticancer agent with immunomodulatory properties. , 2013, Colloids and surfaces. B, Biointerfaces.

[131]  Masashi Kato,et al.  Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model , 2013, The Journal of Immunology.

[132]  Y. Tundidor,et al.  Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response , 2013, Cancer Immunology, Immunotherapy.

[133]  M. Zucchetti,et al.  Role of macrophage targeting in the antitumor activity of trabectedin. , 2013, Cancer cell.

[134]  Jonathan B. Mitchem,et al.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. , 2013, Cancer research.

[135]  H. Singh‐Jasuja,et al.  Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901 , 2013, Oncoimmunology.

[136]  Yuquan Wei,et al.  Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature , 2012, PloS one.

[137]  Wilfrid Boireau,et al.  Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth , 2012, Nature Medicine.

[138]  M. Lustberg.  Management of neutropenia in cancer patients. , 2012, Clinical advances in hematology & oncology : H&O.

[139]  L. Zitvogel,et al.  Anticancer activity of cardiac glycosides , 2012, Oncoimmunology.

[140]  S. Raikin,et al.  Risk factors for wound complications after ankle fracture surgery. , 2012, The Journal of bone and joint surgery. American volume.

[141]  J. Ricci,et al.  Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response , 2012, Proceedings of the National Academy of Sciences.

[142]  L. Zitvogel,et al.  Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death , 2012, Science Translational Medicine.

[143]  V. Seshan,et al.  A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis , 2012, Cell.

[144]  J. Neal,et al.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  L. Zitvogel,et al.  Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer , 2012, Oncoimmunology.

[146]  Liangfang Zhang,et al.  Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. , 2012, Biochemical pharmacology.

[147]  Xiang Huang,et al.  Preconditioning chemotherapy with cisplatin enhances the antitumor activity of cytokine-induced killer cells in a murine melanoma model. , 2012, Cancer biotherapy & radiopharmaceuticals.

[148]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[149]  J. Jonkers,et al.  Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system , 2012, Nature Medicine.

[150]  J. Hodge,et al.  Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing. , 2012, Cancer biotherapy & radiopharmaceuticals.

[151]  E. Brogi,et al.  Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. , 2011, Genes & development.

[152]  M. Oka,et al.  Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity. , 2011, Anticancer research.

[153]  Y. Najjar,et al.  Anti‐PD‐1 synergizes with cyclophosphamide to induce potent anti‐tumor vaccine effects through novel mechanisms , 2011, European journal of immunology.

[154]  A. Scherag,et al.  Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas , 2011, Journal of Translational Medicine.

[155]  Liangfang Zhang,et al.  Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. , 2011, Molecular pharmaceutics.

[156]  C. Figdor,et al.  Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. , 2011, The Journal of clinical investigation.

[157]  S. Loi,et al.  Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. , 2011, Cancer research.

[158]  J. Fucikova,et al.  Human tumor cells killed by anthracyclines induce a tumor-specific immune response. , 2011, Cancer research.

[159]  M. Iordanov,et al.  Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome , 2011, Cancer biology & therapy.

[160]  A. V. D. Van Der Zee,et al.  Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis , 2011, British Journal of Cancer.

[161]  L. Zitvogel,et al.  Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress , 2011, Oncogene.

[162]  Jimin Gao,et al.  Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer , 2011, Cancer Immunology, Immunotherapy.

[163]  J. Wigginton,et al.  Anti‐tumour synergy of cytotoxic chemotherapy and anti‐CD40 plus CpG‐ODN immunotherapy through repolarization of tumour‐associated macrophages , 2011, Immunology.

[164]  B. Seal,et al.  A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer , 2011, Journal of medical economics.

[165]  M. Seymour,et al.  Balancing the efficacy and toxicity of chemotherapy in colorectal cancer , 2011, Therapeutic advances in medical oncology.

[166]  S. Singhal,et al.  Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[167]  Robert Langer,et al.  Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy , 2010, Proceedings of the National Academy of Sciences.

[168]  C. Liu,et al.  Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway. , 2010, Cellular and molecular biology.

[169]  Raimar Löbenberg,et al.  Secondary cytotoxicity mediated by alveolar macrophages: a contribution to the total efficacy of nanoparticles in lung cancer therapy? , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[170]  Liangfang Zhang,et al.  Nanoparticle-assisted combination therapies for effective cancer treatment. , 2010, Therapeutic delivery.

[171]  D. Gilvary,et al.  A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers , 2010, Clinical Cancer Research.

[172]  K. Ulbrich,et al.  Synergistic action of doxorubicin bound to the polymeric carrier based on N-(2-hydroxypropyl)methacrylamide copolymers through an amide or hydrazone bond. , 2010, Molecular pharmaceutics.

[173]  A. Aboussekhra,et al.  Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule , 2010, Breast Cancer Research.

[174]  J. Wolchok,et al.  Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. , 2010, Blood.

[175]  N. Harashima,et al.  Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma , 2010, Cancer Immunology, Immunotherapy.

[176]  J. Vincent,et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.

[177]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[178]  Marina A Dobrovolskaia,et al.  Nanoparticles and the immune system. , 2010, Endocrinology.

[179]  Jun Shi,et al.  The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy , 2010, Cancer Immunology, Immunotherapy.

[180]  J. Pignon,et al.  Immunogenic death of colon cancer cells treated with oxaliplatin , 2010, Oncogene.

[181]  Xueying Sun,et al.  Low-Dose Metronomic Paclitaxel Chemotherapy Suppresses Breast Tumors and Metastases in Mice , 2010, Cancer investigation.

[182]  Steven Piantadosi,et al.  Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[183]  B. Thürlimann,et al.  The Role of Combination Chemotherapy in the Treatment of Patients with Metastatic Breast Cancer , 2009, Breast Care.

[184]  María J. Vicent,et al.  Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. , 2009, Advanced drug delivery reviews.

[185]  Ashutosh Chilkoti,et al.  Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumors after a single injection , 2009, Nature materials.

[186]  C. Kim,et al.  Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model , 2009, Clinical and Vaccine Immunology.

[187]  J. Tschopp,et al.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors , 2009, Nature Medicine.

[188]  Guido Bocci,et al.  Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. , 2009, European journal of pharmacology.

[189]  A. Chang,et al.  In Vivo Sensitized and In Vitro Activated B Cells Mediate Tumor Regression in Cancer Adoptive Immunotherapy1 , 2009, The Journal of Immunology.

[190]  T. Whiteside,et al.  TLR4 signaling induced by lipopolysacharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer , 2009, Oncogene.

[191]  M. Tsan,et al.  Heat shock proteins and immune system , 2009, Journal of leukocyte biology.

[192]  J. Lee,et al.  Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.

[193]  M. Zucchetti,et al.  Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. , 2009, European journal of cancer.

[194]  D. Ghersi,et al.  Single agent versus combination chemotherapy for metastatic breast cancer. , 2009, The Cochrane database of systematic reviews.

[195]  E. Montero,et al.  Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine. , 2009, Vaccine.

[196]  F. Ghiringhelli,et al.  Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model , 2009, Cancer Immunology, Immunotherapy.

[197]  J. Tschopp,et al.  Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome , 2009, Proceedings of the National Academy of Sciences.

[198]  Yong Lin,et al.  Tumor necrosis factor and cancer, buddies or foes? , 2008, Acta Pharmacologica Sinica.

[199]  D. Greiner,et al.  Creation of “Humanized” Mice to Study Human Immunity , 2008, Current protocols in immunology.

[200]  J. Slingerland,et al.  A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer. , 2008, Clinical breast cancer.

[201]  Ping Zhang,et al.  Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. , 2008, Molecular immunology.

[202]  T. Guo,et al.  Regulation of Hepatic Drug-Metabolizing Enzyme Genes by Toll-Like Receptor 4 Signaling Is Independent of Toll-Interleukin 1 Receptor Domain-Containing Adaptor Protein , 2008, Drug Metabolism and Disposition.

[203]  J. Stanslas,et al.  Changes in Cellular Immunity during Chemotherapy for Primary Breast Cancer with Anthracycline Regimens , 2007, Journal of chemotherapy.

[204]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[205]  Omid C Farokhzad,et al.  Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates , 2007, ChemMedChem.

[206]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[207]  A. García-Sastre,et al.  Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells. , 2007, Cancer research.

[208]  P. Okunieff,et al.  Enhanced Antitumor Effect of Combined Triptolide and Ionizing Radiation , 2007, Clinical Cancer Research.

[209]  L. Mayer,et al.  Optimizing combination chemotherapy by controlling drug ratios. , 2007, Molecular interventions.

[210]  B. Chauffert,et al.  Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.

[211]  Frank Bates,et al.  Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[212]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[213]  M. Bally,et al.  Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice , 2006, Molecular Cancer Therapeutics.

[214]  P. Couvreur,et al.  Nanotechnology: Intelligent Design to Treat Complex Disease , 2006, Pharmaceutical Research.

[215]  E. Stanley,et al.  Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. , 2006, Cancer research.

[216]  J. Schlom,et al.  Combination Chemotherapy and Radiation of Human Squamous Cell Carcinoma of the Head and Neck Augments CTL-Mediated Lysis , 2006, Clinical Cancer Research.

[217]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[218]  L. Zitvogel,et al.  Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death , 2005, The Journal of experimental medicine.

[219]  L. Zitvogel,et al.  Trial watch , 2012, Oncoimmunology.

[220]  D. Sargent,et al.  Cost‐effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first‐line therapy for metastatic colorectal carcinoma , 2005, Cancer.

[221]  L. Galluzzi,et al.  Trial watch , 2012, Oncoimmunology.

[222]  L. Kaiser,et al.  Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.

[223]  G. Lyman,et al.  Risk models for predicting chemotherapy-induced neutropenia. , 2005, The oncologist.

[224]  J. Schlom,et al.  Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. , 2005, Blood.

[225]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[226]  S. Shott,et al.  Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas , 2005, Cancer Immunology, Immunotherapy.

[227]  J. Pignon,et al.  Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. , 2004, JAMA.

[228]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[229]  Timothy R. Crespin,et al.  Cellular Immunity in Breast Cancer Patients Completing Taxane Treatment , 2004, Clinical Cancer Research.

[230]  G. Lyman,et al.  Chemotherapy‐induced neutropenia , 2004, Cancer.

[231]  M. D’Incalci,et al.  Preclinical and clinical results with the natural marine product ET-743 , 2003, Expert opinion on investigational drugs.

[232]  S. Buttiglieri,et al.  Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells , 2003, Anti-cancer drugs.

[233]  T. Schöndorf,et al.  Hematological side-effect profiles of individualized chemotherapy regimen for recurrent ovarian cancer , 2003, Anti-cancer drugs.

[234]  M. Zucchetti,et al.  Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies , 2003, Cancer Chemotherapy and Pharmacology.

[235]  J. Frelinger,et al.  Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1 , 2003, The Journal of Immunology.

[236]  R. O’Hara,et al.  Species decline—but why? Explanations of carabid beetle (Coleoptera, Carabidae) declines in Europe , 2003, Oecologia.

[237]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[238]  F. Marincola,et al.  A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma , 2002, Journal of immunotherapy.

[239]  H. Weiner,et al.  Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects , 2002, Multiple sclerosis.

[240]  K. Ulbrich,et al.  Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[241]  E. Bergmann-Leitner,et al.  Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes , 2001, Cancer Immunology, Immunotherapy.

[242]  D. Banerjee,et al.  Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[243]  W. Symmans,et al.  Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[244]  K. Ulbrich,et al.  Immunoprotective therapy with targeted anticancer drugs , 2001 .

[245]  J. Leonard,et al.  The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses. , 2001, Blood.

[246]  J. Permert,et al.  A Systematic Overview of Chemotherapy Effects in Pancreatic Cancer , 2001 .

[247]  G. Peters,et al.  Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines , 2000, British Journal of Cancer.

[248]  K. Yamasawa,et al.  Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface. , 2000, Anticancer research.

[249]  J. Misset,et al.  Oxaliplatin clinical activity: a review. , 2000, Critical reviews in oncology/hematology.

[250]  A. Kaider,et al.  Transient increase in mitogen-induced lymphoproliferative responses in patients with testicular cancer after BEP chemotherapy. , 2000, Urology.

[251]  R. Purcell,et al.  Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo1 , 2000, The Journal of Immunology.

[252]  D. Ito,et al.  Synergistic induction of ICAM-1 expression by cisplatin and 5-fluorouracil in a cancer cell line via a NF-κB independent pathway , 1999, British Journal of Cancer.

[253]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[254]  H. Weiner,et al.  Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin‐4 production and associated eosinophilia , 1997, Annals of neurology.

[255]  M. Bally,et al.  The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. , 1997, The Journal of pharmacology and experimental therapeutics.

[256]  S. Vogel,et al.  Paclitaxel (Taxol)-induced NF-kappaB translocation in murine macrophages , 1996, Infection and immunity.

[257]  D. Grisaru,et al.  Prenatal sonographic diagnosis of intermembranous abruptio placentae in a twin pregnancy. , 1994, Journal of ultrasound in medicine.

[258]  A. Hall,et al.  Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. , 1992, Blood reviews.

[259]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[260]  E. Tartour,et al.  Immunomodulatory Activity of VEGF in Cancer. , 2017, International review of cell and molecular biology.

[261]  J. Hubbell,et al.  Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. , 2014, Biomaterials.

[262]  S. Lippard,et al.  Understanding and improving platinum anticancer drugs--phenanthriplatin. , 2014, Anticancer research.

[263]  Jonathan P Schneck,et al.  Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. , 2014, Biomaterials.

[264]  G. Pillai,et al.  Nanomedicines for Cancer Therapy : An Update of FDA Approved and Those under Various Stages of Development , 2014 .

[265]  S. Lippard,et al.  Understanding and Improving Platinum Anticancer Drugs , 2014 .

[266]  Chih-Long Chang,et al.  Dose-dense chemotherapy improves mechanisms of antitumor immune response. , 2013, Cancer research.

[267]  P. Fisher,et al.  Therapeutic cancer vaccines: past, present, and future. , 2013, Advances in cancer research.

[268]  C. Figdor,et al.  Targeting nanoparticles to dendritic cells for immunotherapy. , 2012, Methods in enzymology.

[269]  R. Kerbel,et al.  Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. , 2011, Neoplasia.

[270]  Lawrence Mayer,et al.  In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. , 2009, Leukemia research.

[271]  M. Nishimura,et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy , 2008, Cancer Immunology, Immunotherapy.

[272]  L. Zitvogel,et al.  Immunological aspects of cancer chemotherapy , 2008, Nature Reviews Immunology.

[273]  S. Ramalingam,et al.  Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. , 2008, The oncologist.

[274]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.

[275]  M. Citardi,et al.  Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine , 2005, Journal of Cancer Research and Clinical Oncology.

[276]  J. Hornaday,et al.  Cancer Facts & Figures 2004 , 2004 .

[277]  S. Kaye,et al.  New antimetabolites in cancer chemotherapy and their clinical impact. , 1998, British Journal of Cancer.